论文部分内容阅读
目的:观察复方苦参注射液联合奈达铂治疗恶性胸腔积液的临床疗效。方法:将全部恶性胸腔积液患者72例,采用随机抽样方法分为治疗组与对照各36例。治疗组在胸水引流后采用复方苦参注射液联合奈达铂和地塞米松胸腔内注射治疗,药物剂量为复方苦参注射液30 m L、0.9%氯化钠注射液50 m L、奈达铂60 mg、地塞米松10 mg。对照组在胸水引流后单纯采用奈达铂合地塞米松胸腔内注射治疗,药物剂量同治疗组。治疗5~7 d后重复治疗1次,最多重复4次。治疗结束后观察两组疗效、生活质量、不良反应情况,并作比较。结果:治疗组总缓解率和生存质量KPS评分改善稳定率明显高于对照组(P<0.05);治疗组消化道症状和白细胞计数下降发生率明显低于对照组(P<0.05)。结论:复方苦参注射液联合奈达铂疗法可有效提高恶性胸腔积液疗效,改善患者生存质量。
Objective: To observe the clinical curative effect of compound Kushen injection combined with nedaplatin in the treatment of malignant pleural effusion. Methods: 72 patients with malignant pleural effusion were randomly divided into treatment group and control group with 36 cases each. The treatment group was treated with compound Kushen injection combined with intradermal injection of nedaplatin and dexamethasone after the hydrothorax was drained. The drug dose was 30 m L of Compound Kushen Injection, 50 m L of 0.9% Sodium Chloride Injection, Platinum 60 mg, dexamethasone 10 mg. The control group was treated with intradermal injection of nedaplatin and dexamethasone only after pleural effusion, and the drug dose was the same as that of the treatment group. Treatment 5 to 7 d after repeated treatment 1, up to 4 times repeated. After treatment, the curative effect, quality of life and adverse reactions of the two groups were observed and compared. Results: The improvement rate of total remission rate and quality of life KPS score in treatment group was significantly higher than that in control group (P <0.05). The incidence of gastrointestinal symptoms and leucocyte count decrease in treatment group was significantly lower than that in control group (P <0.05). Conclusion: Compound Kushen injection combined with nedaplatin therapy can effectively improve the efficacy of malignant pleural effusion and improve the quality of life of patients.